The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD ... associated with Huntington’s disease (HD) just a week ago.

Artificial Intelligence Model Identifies Potential Risk Genes for Parkinson's Disease Jan. 28, 2025 — Researchers have successfully applied advanced artificial intelligence (AI) genetics models ...

Feb. 7, 2025 — Women who have experienced pregnancy complications have an increased risk of cardiovascular disease. Now, a new study shows that sisters of women with complicated pregnancies are ...

A short educational activity on tardive dyskinesia significantly improved clinicians’ confidence in managing and choosing therapies. Separate studies recently published in the European Journal of ...

His doctoral research related to the regulation of upper-gastrointestinal motor and sensory function in health and disease, with an emphasis on the effects of variations in the blood glucose ...

2-Year U.S. Treasury Note Continuous Contract $102.754 0.090 0.09% 5-Year U.S. Treasury Note Continuous Contract $106.484 0.219 0.21% 10-Year U.S. Treasury Note Continuous Contract $109.266 0.297 ...

Tardive dyskinesia is primarily associated with the use of certain medications, particularly antipsychotic medications used to treat conditions like schizophrenia, bipolar disorder, and other ...

After hours: February 14 at 6:00:05 PM EST Loading Chart for PD ...

DAX Futures 22898.00 37.00 0.16% ...

In plain language. Written by scientists. For the global HD community.